Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CSLCSLLY -4.84%73 Days Sales Outstanding is 70.86 as of Dec. 2025, which is 46% above its 10-year median of 48.68. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $49.99 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 836 Biotechnology companies, CSL ranks worse than 80.62% on this metric.
CSL's average Accounts Receivable for the
six
months ended in Dec. 2025 was $3,142 Mil. CSL's Revenue for the
six
months ended in Dec. 2025 was $8,092 Mil.
Hence, CSL's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 70.86.
The historical rank and industry rank for CSL's Days Sales Outstanding or its related term are showing as below:
CSLLY'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 32.5 Med: 48.68 Max: 142.78
Current: 142.78
During the past 13 years, CSL's highest Days Sales Outstanding was 142.78. The lowest was 32.50. And the median was 48.68.
CSLLY's Days Sales Outstanding is ranked worse than 80.62% of 836
companies
in the Biotechnology industry
Industry Median: 68.725
vs CSLLY: 142.78
CSL's Days Sales Outstanding
declined
from Jun. 2024 (73.67) to Dec. 2025 (70.86).
CSL (OTCPK:CSLLY) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
CSL Days Sales Outstanding Related Terms
CSL Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for CSL's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSLLY vs VRTX, REGN, RVMD: Days Sales Outstanding Comparison
For the Biotechnology subindustry, CSL's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where CSL's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSL (CSLLY) has a Days Sales Outstanding of 70.86 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on CSL and its competitors. This is 46% above median its historical median of 48.68. Over the past decade, CSL's Days Sales Outstanding has ranged from 32.50 to 142.78. According to the industry distribution chart, CSL ranks #674 out of 836 companies in the Biotechnology industry, placing it in the top 80.6%.
Is CSL's Days Sales Outstanding too high?
CSL's current Days Sales Outstanding of 70.86 is 46% above median its 10-year median of 48.68. Over the past 10 years, this metric has ranged from a low of 32.50 to a high of 142.78. The Biotechnology industry median Days Sales Outstanding is 68.73. CSL's value of 70.86 is 3.1% above this industry median. Based on the distribution chart, CSL ranks #674 out of 836 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #674 out of 836 companies for Days Sales Outstanding. This places CSL in the lower half of its industry. The industry median Days Sales Outstanding is 68.73. CSL's value of 70.86 is 3.1% above this benchmark. Historically, CSL's own Days Sales Outstanding has ranged from 32.50 to 142.78 over the past decade. While the company's 10-year median is 48.68 vs. the industry median of 68.73, CSL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.73, based on 836 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSL's current Days Sales Outstanding of 70.86 is 3.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on CSL and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSL's current Days Sales Outstanding is 70.86, which is 46% above median its own 10-year median of 48.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $49.99, compared to a current price of $21.61 — trading 56.8% below its estimated fair value. The current Days Sales Outstanding is 70.86, which is 46% above median its 10-year median of 48.68 and 3.1% above the Biotechnology industry median of 68.73. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For CSL (CSLLY), the current Days Sales Outstanding is 70.86 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (CSLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of $21.61 is trading 56.8% below its estimated GF Value™ of $49.99.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for CSLLY:
Days Sales Outstanding: 70.86 (46% above median its 10-year median of 48.68)
GF Value™: $49.99 vs. price of $21.61 (56.8% below fair value)
Industry Position: 3.1% above the Biotechnology median (#674 of 836)
No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for CSLLY
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSLLY has been successfully added to your 
